Cargando…

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer

Immunotherapy has recently become widely used in lung cancer. Many oncologists are focused on cytotoxic T lymphocyte antigen‐4 (CTLA‐4), programmed cell death ligand‐1 (PD‐L1) and programmed cell death‐1 (PD‐1). Immunotherapy targeting the PD‐1/PD‐L1 checkpoints has shown promising efficacy in non‐s...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yayi, Rivard, Christopher J., Rozeboom, Leslie, Yu, Hui, Ellison, Kim, Kowalewski, Ashley, Zhou, Caicun, Hirsch, Fred R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021038/ https://www.ncbi.nlm.nih.gov/pubmed/27297395 http://dx.doi.org/10.1111/cas.12986

Ejemplares similares

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules
por: He, Yayi, et al.
Publicado: (2017)

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status
por: Suda, Kenichi, et al.
Publicado: (2017)

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
por: Liu, Yu, et al.
Publicado: (2021)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse
por: Guo, Haoyue, et al.
Publicado: (2021)

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
por: Suda, Kenichi, et al.
Publicado: (2017)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2(nd)/3(rd) Line Therapy in Patients with Lung Adenocarcinoma
por: He, Yayi, et al.
Publicado: (2016)

sLAG-3 in non-small-cell lung cancer patients’ serum
por: He, Yayi, et al.
Publicado: (2018)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Treatment of spine metastases in cancer: a review
por: Chen, Yu, et al.
Publicado: (2019)

Loss of STING expression is prognostic in non–small cell lung cancer
por: Lohinai, Zoltan, et al.
Publicado: (2022)

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

Risk factors for nicotine dependence in Chinese patients with lung cancer
por: Gu, Fen, et al.
Publicado: (2018)

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
por: Dora, David, et al.
Publicado: (2020)

cGAS-STING, an important pathway in cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2020)

T lymphocyte-targeted immune checkpoint modulation in glioma
por: Kelly, William James, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis
por: Amin, Shefali, et al.
Publicado: (2023)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors
por: Liu, Sangtian, et al.
Publicado: (2020)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer
por: Zhang, Liping, et al.
Publicado: (2015)

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer
por: He, Yayi, et al.
Publicado: (2016)

The CD83 Molecule – An Important Immune Checkpoint
por: Grosche, Linda, et al.
Publicado: (2020)

Correction: T lymphocyte-targeted immune checkpoint modulation in glioma
Publicado: (2020)

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
por: Pesce, Silvia, et al.
Publicado: (2020)

Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
por: Shi, Tao, et al.
Publicado: (2018)

An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC)
por: Guo, Haoyue, et al.
Publicado: (2021)

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer
por: Dai, Jiawei, et al.
Publicado: (2021)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis
por: Khan, Jaffar, et al.
Publicado: (2021)

TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia
por: Seiffert, Martina
Publicado: (2023)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review
por: Song, Xinyu, et al.
Publicado: (2021)

Killer immunoglobulin-like receptors/human leukocyte antigen class-I, a crucial immune pathway in cancer
por: Xu, Yi, et al.
Publicado: (2020)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

PD-1 and its ligands are important immune checkpoints in cancer
por: Dong, Yinan, et al.
Publicado: (2016)

Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma
por: Vermeulen, Jeroen F., et al.
Publicado: (2017)

Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction
por: Landeira-Viñuela, Alicia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gf5rca4hv6kh459aasum7djpru